CalcMyPeptide
Khavinson BioregulatorAlso known as: Ala-Glu-Asp, AED, Cartilage Bioregulator

Cartalax

Khavinson tripeptide bioregulator (Ala-Glu-Asp) targeting cartilage tissue — studied for chondroprotection, joint health, and osteoarthritis-related cartilage degeneration.

Half-Life
~30 minutes (estimated)
Dose Range
10-20 mg/day (oral) or 1-2 mg SC
Frequency
1× daily for 10-30 day cycles
Vial Sizes
5 mg, 10 mg

🔬 Mechanism of Action

Cartalax (Ala-Glu-Asp, AED) is a synthetic tripeptide bioregulator targeting cartilage tissue, designed at the Saint Petersburg Institute of Bioregulation and Gerontology. The AED sequence was identified through bioactivity-guided fractionation of cartilage-derived peptide pools.

Cartalax regulates chondrocyte gene expression for proteoglycan core proteins (aggrecan, decorin), collagen type II alpha chains, and matrix metalloproteinase inhibitors (TIMPs). In cell culture studies, Cartalax treatment of human chondrocytes increased glycosaminoglycan synthesis by 30-40% and reduced MMP-13 expression — the collagenase most implicated in osteoarthritic cartilage destruction.

Cartalax is one of only three Khavinson peptides targeting musculoskeletal tissue (alongside Sigumir extract and Gotratix for muscle). It represents the synthetic approach to cartilage bioregulation, offering more precise targeting compared to the multi-peptide Sigumir Cytomax extract.

Source: PMID: 15677927

📜Background & History

Cartalax (Ala-Glu-Asp) is the synthetic cartilage bioregulator, targeting chondrocyte gene expression for proteoglycan and collagen type II synthesis.

🎯 Research Use Cases

  • Osteoarthritis support
  • Cartilage maintenance in aging
  • Joint health protocols

💉 Dosing Protocol

Typical Dose10-20 mg/day (oral) or 1-2 mg SC
Frequency1× daily for 10-30 day cycles
Half-Life~30 minutes (estimated)
Common Vial Sizes5 mg, 10 mg

🧪 Reconstitution Example

Vial
5 mg
Water
2.5 mL
Concentration
2 mg/mL
Per Unit (100u syringe)
20 mcg
Dose of 1000 mcg = 50 units on a 100-unit insulin syringe

⚠️Safety & Considerations

Standard Khavinson 10-30 day cycles. Well tolerated. Can be combined with Sigumir (cartilage/bone extract) for comprehensive joint support.

Interactions & Contraindications

Standard Khavinson protocol.

🔗Synergies & Common Stacks

Cartalax (synthetic tripeptide) + Sigumir (cartilage/bone Cytomax extract) = layered musculoskeletal support.

📊 Dosing Quick Reference

Cartalax— Dosing Guide
Dose Range
10-20 mg/day (oral) or 1-2 mg SC
Half-Life
~30 minutes (estimated)
Frequency
1× daily for 10-30 day cycles
Route
Subcutaneous
5 mg vial10 mg vial
💧 2.5 mL BAC water📐 2 mg/mL concentration💉 20 mcg/unit (100u syringe)
Khavinson Bioregulatorcalcmypeptide.com

Frequently Asked Questions

Can Cartalax help with osteoarthritis?
Cartalax targets chondrocytes — the cells responsible for cartilage maintenance. By regulating genes for proteoglycan and collagen synthesis, it may support cartilage health in degenerative joint conditions. It is often combined with Sigumir (the cartilage Cytomax extract) in Khavinson protocols.
How is Cartalax different from glucosamine?
Glucosamine provides raw building blocks for cartilage matrix. Cartalax works at the gene expression level, telling chondrocytes to produce more proteoglycans and less destructive enzymes. They operate through completely different mechanisms and can be used together.